Quarterly report pursuant to Section 13 or 15(d)

Segment, Geographical and Other Revenue Information - Segment Reporting (Details)

v3.21.1
Segment, Geographical and Other Revenue Information - Segment Reporting (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Segment Reporting Information [Line Items]    
Total revenues $ 18,032 $ 14,670
Cost of product revenue 4,218 2,541
Research and development 11,571 10,967
Selling, general and administrative 11,398 8,989
Total costs and operating expenses 27,187 22,497
Income (loss) from operations (9,155) (7,827)
Unallocated depreciation and amortization (659) (438)
Income (loss) before income taxes (9,066) (7,647)
Stock-based compensation 2,687 2,169
Performance Enzymes [Member]    
Segment Reporting Information [Line Items]    
Total revenues 14,229 10,874
Novel Biotherapeutics [Member]    
Segment Reporting Information [Line Items]    
Total revenues 3,803 3,796
Operating Segments [Member]    
Segment Reporting Information [Line Items]    
Total revenues 18,032 14,670
Cost of product revenue 4,218 2,541
Research and development 11,049 10,621
Selling, general and administrative 3,418 2,936
Total costs and operating expenses 18,685 16,098
Income (loss) from operations (653) (1,428)
Stock-based compensation 2,687 2,169
Operating Segments [Member] | Performance Enzymes [Member]    
Segment Reporting Information [Line Items]    
Total revenues 14,229 10,874
Cost of product revenue 4,218 2,541
Research and development 6,444 5,696
Selling, general and administrative 2,818 2,345
Total costs and operating expenses 13,480 10,582
Income (loss) from operations 749 292
Stock-based compensation 994 756
Operating Segments [Member] | Novel Biotherapeutics [Member]    
Segment Reporting Information [Line Items]    
Total revenues 3,803 3,796
Cost of product revenue 0 0
Research and development 4,605 4,925
Selling, general and administrative 600 591
Total costs and operating expenses 5,205 5,516
Income (loss) from operations (1,402) (1,720)
Stock-based compensation 238 241
Corporate [Member]    
Segment Reporting Information [Line Items]    
Total costs and operating expenses (7,728) (5,727)
Unallocated depreciation and amortization (685) (492)
Income (loss) before income taxes (9,066) (7,647)
Stock-based compensation 1,455 1,172
Product Revenue [Member]    
Segment Reporting Information [Line Items]    
Total revenues 10,226 5,100
Product Revenue [Member] | Performance Enzymes [Member]    
Segment Reporting Information [Line Items]    
Total revenues 10,226 5,100
Product Revenue [Member] | Novel Biotherapeutics [Member]    
Segment Reporting Information [Line Items]    
Total revenues 0 0
Product Revenue [Member] | Operating Segments [Member]    
Segment Reporting Information [Line Items]    
Total revenues 10,226 5,100
Product Revenue [Member] | Operating Segments [Member] | Performance Enzymes [Member]    
Segment Reporting Information [Line Items]    
Total revenues 10,226 5,100
Product Revenue [Member] | Operating Segments [Member] | Novel Biotherapeutics [Member]    
Segment Reporting Information [Line Items]    
Total revenues 0 0
Research and Development Revenue [Member]    
Segment Reporting Information [Line Items]    
Total revenues 7,806 9,570
Research and Development Revenue [Member] | Performance Enzymes [Member]    
Segment Reporting Information [Line Items]    
Total revenues 4,003 5,774
Research and Development Revenue [Member] | Novel Biotherapeutics [Member]    
Segment Reporting Information [Line Items]    
Total revenues 3,803 3,796
Research and Development Revenue [Member] | Operating Segments [Member]    
Segment Reporting Information [Line Items]    
Total revenues 7,806 9,570
Research and Development Revenue [Member] | Operating Segments [Member] | Performance Enzymes [Member]    
Segment Reporting Information [Line Items]    
Total revenues 4,003 5,774
Research and Development Revenue [Member] | Operating Segments [Member] | Novel Biotherapeutics [Member]    
Segment Reporting Information [Line Items]    
Total revenues $ 3,803 $ 3,796